With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...

Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

Vertex Pharmaceuticals (VRTX) closed the most recent trading ... estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report ... points to a potential upside of 20.95% from the stock’s current price. Other equities analysts also recently issued research reports ...

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...